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Background: Paroxysmal atrial ﬁbrillation (AF) patients have a reduced quality-of-life (QoL) despite the
fact that the majority of AF episodes are asymptomatic. Asymptomatic AF is likely to be associated with
substantial morbidity andmortality rates similar to thosewith symptomatic AF, whereas its effect on the
QoL has not yet been clariﬁed.
Purpose: We studied the speciﬁc contribution of asymptomatic AF episodes to reducing the QoL.
Methods: We assessed the QoL in 233 patients with paroxysmal AF and hypertension (age 64.9±9.7
years, 71% male) enrolled in the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM
II study) using an AF-speciﬁc QoL questionnaire (AFQLQ). The AFQLQ comprised 3 components: AFQLQ1,
the frequency and duration of symptoms; AFQLQ2, severity of symptoms; and AFQLQ3, limitations in
daily activities and mental anxiety. Higher scores indicated a better QoL. Each patient transmitted elec-
trocardiograms for 30 s daily at a predetermined time aswell aswhenever arrhythmia-related symptoms
were experienced. We examined the relationship between the 3 AFQLQ components and frequency of
symptomatic and asymptomatic AF episodes (days/month) during 12 months of follow-up.
Results: The symptomatic and asymptomatic AF frequencies were 0.9±3.1 days/month and 1.5±3.5
days/month, respectively. AFQLQ1negatively correlatedwith the symptomaticAF frequency (Spearman’s
correlation coefﬁcient: r=−0.332, p<0.001). AFQLQ2 and AFQLQ3 correlated with both the symptomatic
AF frequency (r=−0.27, p<0.001 and r=−0.265, p<0.001, respectively) and asymptomatic AF frequency
(r=−0.197, p<0.01 and r=−0.229, p<0.005, respectively).
Conclusion: The asymptomatic AF episode frequency correlates with a reduced QoL in patients with
paroxysmal AF, suggesting that there would be psychological beneﬁts to its reduction.
4 Jap© 201
ntroductionAtrial ﬁbrillation (AF) remains the most common sustained
rrhythmia in clinical practice and is associated with increased
orbidity and mortality [1–4]. AF also causes a signiﬁcant
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reduction in the quality of life (QoL) compared to age- or sex-
matched healthy subjects [5–7] as well as patients with other
cardiac diseases [5,8–11]. This reduced QoL is well known to be
associatedwith the frequency or severity of symptoms such as pal-
pitations, fatigue, or shortness of breath [7,12,13]. Other factors
associated with a reduced QoL include demographic factors such
as the age and sex, and various comorbidities including heart fail-
ure, hypertension, ischemic heart disease, diabetes, and chronic
obstructive pulmonary disease. The need to be on chronic medi-
cation, as well as dietary or physical activity restrictions are also
negatively correlated with the reduced QoL [5–8,10]. However,
to the best of our knowledge there have been no corresponding
vier Ltd. All rights reserved.
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tudies to date quantifying the relationship between asymptomatic
F burden and the QoL [14]. This is likely due to the difﬁculty of
etecting asymptomatic AF. The studies that have looked at data
ogs of cardiac implantable electronic devices have shown a high
ncidence of asymptomatic AF episodes [15–18]. According to three
ifferent studies, among patients with symptomatic bradycardia
nd a history of AF, asymptomatic AFwas observed in 38% [16], 65%
15], and more than 90% [17] of patients. The Cardiac Arrhythmias
ndRisk StratiﬁcationAfterAcuteMyocardial Infarction (CARISMA)
tudy showed that 88% of AF episodes stored in the implantable
oop recorders were clinically silent [18]. Data from the Canadian
egistry of Atrial Fibrillation (CARAF) [19] and Atrial Fibrillation
ollow-up Investigation of Rhythm Management (AFFIRM) study
20] using AF symptom checklists reported that 12–21% of patients
ith a diagnosis of AF did not have any overt symptoms. Given the
igh numbers of AF patients with asymptomatic episodes of AF, it
ould be useful to knowwhether asymptomatic AF affects the QoL
s much as symptomatic AF does.
Secondly, in patients with paroxysmal AF, there appears to be
n inexorable progression to persistent AF at a rate of about 5–9%
er year [21,22], so that over time, the majority of patients end
p with persistent AF. Previous studies comparing the QoL in dif-
erent types of AF in a cross-sectional design showed that there
ere no signiﬁcant differences in the QoL among patients with
aroxysmal, persistent, andpermanentAF [23]. Todate, fewreports
ave examined the prospective relationship between the QoL and
evelopment of persistent AF.
Therefore, this prospectively designed Japanese Rhythm Man-
gement Trial II for Atrial Fibrillation (J-RHYTHM II study) post
oc study had two aims. One was to measure the QoL using an
F-speciﬁc questionnaire [24–26] in patients with asymptomatic
aroxysmal AF episodes. The second was to quantify the changes
n the QoL before and after the development of persistent AF.
ethods
atient population
Details of the J-RHYTHM II study have been reported previously
27,28]. In brief, 318 patients with paroxysmal AF and hyperten-
ion, deﬁned as a systolic blood pressure ≥140mmHg and/or a
iastolic blood pressure ≥90mmHg, or requiring any hypertension
reatment at enrollment, were randomized to receive either an
ngiotensin II-receptor blocker (ARB) or calcium channel blocker
CCB). The primary endpoint of the study was the frequency of
aroxysmal AF episodes, as days per month. Baseline echocardio-
raphy and a QoL assessment were performed during the ﬁrst 4
eeks after enrollment. After randomization, the assigned therapy
or hypertensionwas initiated in an open-label fashion and contin-
ed throughout the whole follow-up period for a maximum of 12
onths. Each patient was provided with a transtelephonic moni-
oring (TTM) device that included a mobile phone system (Nihon
ohden, Tokyo, Japan) and was requested to transmit electrocar-
iography recordings for 30 s daily at a predetermined time by
atients’ discretion and also at any time arrhythmia-related symp-
oms were experienced. The symptomatic and asymptomatic AF
pisodes were differentiated by the arrhythmia-related symptoms
y selecting a button equipped with the device. All electrocardio-
raphic tracings were reviewed by a blinded, independent TTM
iagnosis laboratory. Each day was classiﬁed as symptomatic AF
r asymptomatic AF, or no AF, and the number of AF days was
allied for the 4 weeks. The total AF was deﬁned as the sum of the
ymptomatic and asymptomatic AF days. If patients transmitted
oth symptomatic AF and asymptomatic AF episodes in a single
ay, it was predetermined to use the symptomatic AF episode andardiology 64 (2014) 64–69 65
not the asymptomatic AF episode. However, we did not have any
patients who transmitted both symptomatic AF and asymptomatic
AF episodes in a single day. We used two periods, the ﬁrst month
before randomization to an ARB or CCB (baseline), and the ﬁnal
month of the 1-year follow-up on these drugs.
Paroxysmal AF was deﬁned as AF expected to convert sponta-
neously to sinus rhythm within 48h of the onset and persistent
AF was deﬁned as AF either lasting longer than consecutive 7 days
or AF requiring termination by pharmacological or electrical car-
dioversion. The study protocol was approved by each institution
and all patients gave their written informed consent.
Assessment of the QoL
We used a questionnaire formulated speciﬁcally for AF patients
called the Atrial Fibrillation Quality of Life Questionnaire (AFQLQ)
[24,25]. The AFQLQ consisted of 3 components: AFQLQ1 assessed
the subjective frequency and duration of symptoms (6 items, 0–24
points); AFQLQ2 assessed the severity of symptoms (6 items, 0–18
points); and AFQLQ3 assessed the limitations in daily and other
activities and mental anxiety related to AF (14 items, 0–56 points).
A higher score indicated a better QoL in every component. The
AFQLQ is considered to be valid and reproducible, with values of
a statistical measure for the reliability called Cronbach’s alpha of
0.78, 0.81, and 0.89 for AFQLQ1, AFQLQ2, and AFQLQ3, respectively
[25]. In general, a Cronbach’s alpha of greater than 0.7 indicates
reliability [29]. An AFQLQ assessment was performed both at
baseline and at the ﬁnal month of the 1-year follow-up. The AFQLQ
was self-administered by the study patients and forwarded to the
core laboratory, where analyses were performed.
Statistical analysis
Data are presented as the mean± standard deviation (SD) for
continuous variables and percentages for categorical variables.
Differences in the quantitative data and categorical data were
evaluated by a Student’s t-test and chi-square test, respectively.
Spearman’s rank correlation analysis was applied to test the
relationships between the clinical variables and AFQLQ, and the
associations between the number of symptomatic AF episodes and
asymptomatic AF episodes. The signiﬁcance of the AFQLQ between
those who developed persistent AF and those who remained in
paroxysmal AF at baseline and 1 year after enrollment, and the
AFQLQbefore andafter theprogression topersistentAFwere tested
by an analysis of variance (ANOVA). A two-tailed p-value of <0.05
was considered signiﬁcant.
Results
From the cohort of the J-RHYTHM II study, a total of 233
patients were included in this post hoc analysis. Patients who
failed to complete the AFQLQ protocol (n=85) in the parent study
were excluded. The baseline clinical characteristics are shown
in Table 1. The mean age was 64.9±9.7 years (range, 38–92
years), and 165 patients (71%) were men. The mean systolic blood
pressure was high as expected from the parent study cohort
(140.5±15.3mmHg). The left ventricular ejection fraction (LVEF)
waswellpreserved (67.4±8.3%), and themean left atrial dimension
(LAD) was 39.0±7.0mm. Few patients had signiﬁcant structural
heart disease.
All patients in the substudy had data for the 12th follow-up
month available. The number of AF days/month (both symptomatic
and asymptomatic) decreased from 4.5±6.0 days at baseline to
2.4±4.5 days at one year (p<0.01). However, there were no
changes in the scores of the 3 components of the AFQLQ between
baseline and at one year (Fig. 1A). There was a gender difference
66 M. Yamamoto et al. / Journal of C
Table 1
Clinical characteristics of the patients.
Characteristics (n=233)
Age, years 64.9±9.7
Male, % 71
Systolic blood pressure, mmHg 140.5±15.3
Diastolic blood pressure, mmHg 82.1±11.1
Duration of AF, %
<1 year 25
≥1 year, <5 years 40
>5 years 25
Unknown 10
Development of persistent AF, % 13
Coexisting conditions, %
Prior embolism 5
Heart failure 3
Myocardial infarction 1
Angina pectoris 2
Dilated cardiomyopathy 0.4
Valve disease 6
Diabetes mellitus 9
Echocardiogram parameter
LVEF, % 67.4±8.3
LAD, mm 39.0±7.0
Rhythm control drug, % 70
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data represent means± SD or % of the study population. AF, atrial ﬁbrillation;
VEF, left ventricular ejection fraction; LAD, left atrial dimension.t baseline for the AFQLQ2, with men having a higher score than
omen (12.7±3.6 vs. 11.3±3.6, p<0.05) (Fig. 1B), although the
otal number of AF days/month in themen andwomen did not sig-
iﬁcantly differ (4.5±6.0 days in men vs. 4.5±6.1 days in women,
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rug therapy and 1-year after follow-up. (B) Sex differences at baseline. (C) Rhythm contardiology 64 (2014) 64–69
p=0.99). This gender difference in the AFQLQ2 score was absent
at the end of the follow-up (13.5±3.8 vs. 13.2±3.5, p=0.55). No
gender difference was observed in the total AF days/month at
the end of follow-up (2.6±4.7 days in men vs. 2.0±4.0 days in
women, p=0.36).
We also examined potentially confounding variables that could
affect the QoL. At baseline, the patients who were not on rhythm
control drugs had a higher AFQLQ3 score with near statistical sig-
niﬁcance (p=0.051) than the patients on rhythm control drugs
(Fig. 1C). Spearman’s rank correlation analyses failed to reveal any
signiﬁcant relationships between the AFQLQ components and the
objective clinical measures such as the age, systolic blood pressure,
duration of AF, LVEF, and LAD (data not shown).
Symptomatic AF and asymptomatic AF
The relationship between the AFQLQ and number of AF
days/month at baseline and at 1 year after enrollment are sum-
marized in Table 2. At baseline, the symptomatic AF days/month
and asymptomatic AF days/month were 1.6±3.2 days and
2.9±5.1 days, respectively. The number of asymptomatic AF
days/month accounted for 64% of the total AF days/month. The
number of symptomatic AF days was signiﬁcantly correlated
with all 3 components of the AFQLQ (Spearman’s correla-
tion coefﬁcient r=−0.326, −0.217, and −0.186 for AFQLQ1,
AFQLQ2, and AFQLQ3 respectively), but the asymptomatic AF
days/monthwere associated onlywith the AFQLQ1 only at baseline
(r=−0.170).
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al AF patients from the J-RHYTHM II substudy. (A) AFQLQ before randomization to
rol drug use at baseline. Data represent the mean± SD. *p<0.05.
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Table 2
Relationship between the AFQLQ and AF days per month.
Total AF Symptomatic AF Asymptomatic AF
Baseline
AF days/month, days 4.5±6.0 1.6±3.2 2.9±5.1
Correlation coefﬁcients
AFQLQ1 −0.338‡ −0.326‡ −0.170*
AFQLQ2 −0.112 −0.217† 0.016
AFQLQ3 −0.034 −0.186** 0.090
1 year after enrollment
AF days/month, days 2.4±4.5 0.9±3.1 1.5±3.5
Correlation coefﬁcients
AFQLQ1 −0.342‡ −0.332‡ −0.114
AFQLQ2 −0.181* −0.270‡ −0.197**
AFQLQ3 −0.123 −0.265‡ −0.229†
Data represent means± SD. Correlation coefﬁcients were determined by a Spear-
man’s rank correlation analysis. The total AF is the sum of the symptomatic and
asymptomatic AF days. AFQLQ, Atrial Fibrillation Quality of Life Questionnaire.
* p<0.05.
** p<0.01.
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Table 3
Comparison of paroxysmal AF patients who did and did not develop persistent AF.
Persistent AF−
(n=203)
Persistent AF+
(n=30)
Age, years 64.7±9.7 66.9±9.9
LVEF, % 67.6±8.0 66.2±10.4
LAD, mm 38.5±6.6 43.2±8.8*
CHADS2 score 1.4±0.7 1.5±0.6
Rhythm control drug, % 69 73
AFQLQ (baseline)
AFQLQ1 15.7±5.3
(n=201)
15.6±5.0
(n=26)
AFQLQ2 12.2±3.7 12.8±3.4
AFQLQ3 44.8±9.6 46.9±9.8
AFQLQ (1 year after enrollment)
AFQLQ1 14.4±4.5
(n=175)
12.4±5.4
(n=23)
AFQLQ2 13.4±3.7
(n=177)
13.6±3.5
(n=22)
AFQLQ3 47.8±8.4
(n=169)
46.6±10.7
(n=21)
Differences
AFQLQ1 −1.5±4.9
(n=165)
−3.3±5.2
(n=23)
AFQLQ2 1.3±3.6
(n=169)
0.7±2.8
(n=21)
AFQLQ3 2.0±7.0
(n=161)
0.2±7.0
(n=19)
Data represent means± SD or the frequency. n indicates the number of patients.
Persistent AF+: patients who developed persistent AF during the follow up; persis-
tent AF−: those who remained in paroxysmal AF during the follow up. CHADS2: an
acronym for congestive heart failure, hypertension, age ≥75, diabetes mellitus, and
a prior stroke or transient ischemic attack. AF, atrial ﬁbrillation; LVEF, left ventricu-
lar ejection fraction; LAD, left atrial dimension; AFQLQ, Atrial Fibrillation Quality of† p<0.005.
‡ p<0.001.
At one year, the symptomatic AF days/month and asymptomatic
F days/monthwere 0.9±3.1 days and 1.5±3.5 days, respectively.
he number of asymptomatic AF days accounted for 63%of the total
F. Again, the symptomatic AF days/month negatively correlated
ith all 3 components of the AFQLQ (AFQLQ1: r=−0.332, AFQLQ2:
=−0.270, and AFQLQ3: r=−0.265). The number of asymptomatic
F days/month was also negatively correlated with the AFQLQ2
r=−0.197) and AFQLQ3 (r=−0.229). There was no statistical sig-
iﬁcance between symptomatic AF days/month and asymptomatic
F days/month (r=−0.122, p=0.06) when we included the results
t baseline and one-year follow-up in the analysis.
rogression to persistent AF
During the follow-up, 30 (13%) patients had progressed to
ersistent AF. The clinical characteristics and AFQLQ of those
ho developed persistent AF (persistent AF+) versus those who
emained in paroxysmal AF (persistent AF−) are summarized in
able 3. The LAD at baseline was larger in those with progression
o persistent AF compared to those who remained in paroxysmal
F (38.5±6.6mmvs. 43.2±8.8mm, p<0.05). Therewere no signif-
cant differences in the 3 components of the AFQLQ between those
ho developed persistent AF and those who remained in paroxys-
al AF either at baseline or 1 year after enrollment. Neither were
here any signiﬁcant differences in the 3 components of the AFQLQ
efore and after the progression to persistent AF.
iscussion
ajor ﬁndings
We investigated the QoL in patients with paroxysmal AF
nrolled in the J-RHYTHM II study using an AF-speciﬁc ques-
ionnaire, the AFQLQ. Based on the data gathered using periodic
nd symptom-related transtelephonic ECGmonitoring, we discov-
red that the QoL was negatively associated with the number of
symptomatic AF days. Further, we found that the progression to
ersistent AF did not decrease the QoL in patients with paroxysmal
F. Our study also conﬁrmed the results of studies in the literature
howing that the burden of symptomatic AF negatively affects the
oL [7,12], and women experienced a subjectively greater severity
f AF symptoms relative to men [9], although there was no dif-
erence in the number of AF days between the sexes in our study.Life Questionnaire.
* p<0.05.
Objective measures of disease severity were not associated with
the QoL, a ﬁnding that has been observed in other studies.
AF-speciﬁc QoL measure
The administration of an AF-speciﬁc QoL test, the AFQLQ, pro-
vided evidence for a reduced QoL in patients with asymptomatic
episodes of AF. In this respect, the scores obtained in the limita-
tions of daily and other activities and the mental anxiety of the
AF-QoL questionnaire (AFQLQ3) would indicate that it is precisely
the patients with asymptomatic episodes of AF who experience a
worse QoL. Internal consistency and reproducibility of AFQLQ was
validated by Yamashita et al. [25]. In that study the completed
questionnaire was obtained twice from 172 stable AF patients at
3–6 months interval. Spearman’s rank correlation coefﬁcients of 3
items were all above 0.7, indicating a positive result. Also, as pre-
sented in Fig. 1 there were no signiﬁcant differences in the average
scores of the 3 components of AFQLQ between baseline and the
end of follow up. We believe that difference in the span of evalu-
ation of this study might not inﬂuence the outcomes. To date, the
AFQLQ has been used for AF studies involving the J-RHYTHM study
[26] and the J-RHYTHM II study [28]. While multiple reports on
the QoL in AF patients have been published, most of them used
genericQoLquestionnaires [7,8,10,14], rather thanAF-speciﬁc ones
[11,23,30]. The strengths of the generic tools used to assess the QoL
in AF include their extensive validation, generalizability, and the
wealth of data already collected on AF patients. The weakness of
the generic measures is, however, that scores among AF patients
are markedly inﬂuenced by patient demographics and comorbid
conditions, because they include questions about general health
and function [10]. We believe AF-speciﬁc questionnaires focused
on domains or symptoms relevant to AF can be more illuminating
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ecause AF patients often have multiple health problems, and are
eterogeneous [31].
oL in AF patients
In the present study, we examined the association between
he AFQLQ and symptomatic AF and asymptomatic AF indepen-
ently. As expected, the number of symptomatic AF days correlated
egatively with all 3 components of the AFQLQ. Interestingly, the
umber of asymptomatic AF days was also negatively associated
ith the AFQLQ2 and AFQLQ3, representing perceived severity of
ymptoms, and limitations in daily activities and mental anxiety.
e found that there was no statistical signiﬁcance between the
umber of symptomatic AF days and asymptomatic AF days; how-
ver, we could not completely exclude the associations between
ymptomatic AF episodes and asymptomatic AF episodes because
f the marginal signiﬁcance. This ﬁnding suggests that the inverse
orrelation between asymptomatic AF episodes and QoL scoremay
e partly mediated by the symptomatic AF episodes. Further, if the
atients who experienced no symptomatic AF episodes but had
nly asymptomatic AF episodes throughout the study period had
educed QoL, itmay support our conclusion; however, we did not
ave such a patient.
Previous studies have reported that AF patients live in fear of
F episodes, and that depression, anxiety, and perceived stress are
ssociated with a reduced QoL in AF patients [32–35]. One of these
tudies by Kupper et al. [35] examined the prospective relationship
etweenAFsymptomsandemotionaldistressbeforeandafter elec-
rical cardioversion in patients with persistent AF. They found that
igher levels of emotional distress including anxiety and perceived
tress continued even in the absence of AF recurrences after elec-
rical cardioversion. The QoL in patients with asymptomatic AF has
lso been reported in a different study design. Savelieva et al. [14]
ompared the QoL using the Medical Outcomes Study Short Form
ealth Survey (SF-36) in healthy subjects, patients with asymp-
omatic AF and symptomatic AF, in which a subset of the Bubien
nd Kay’s symptom checklist [12] was used to categorize whether
atients were asymptomatic. They reported that although most of
he SF-36 scale scores did not differ much between healthy sub-
ects and asymptomatic AF patients, the perception of their general
ealth and global life satisfaction were nevertheless signiﬁcantly
ecreased in the asymptomatic AF patients comparedwith healthy
ubjects. They interpreted their results as suggesting that AF itself
ould signiﬁcantly decrease the overall perception of well-being in
symptomatic AF patients, even though the perception of the QoL
as similar to healthy subjects for speciﬁc social, emotional, and
hysical questions. Our results conﬁrm the ﬁndings of thesemulti-
le studies, and suggest that persistence of anxiety and depression
ecrease the QoL in AF patients even in the absence of AF-related
ymptoms.
Why should asymptomatic AF reduce the QoL? One possibility
s that merely receiving a diagnosis of a chronic disease such as AF
hat can lead to serious consequences such as embolic or hemor-
hagic strokes can induce anxiety and a depressed outlook. Another
s that underlying morbidities leading to atrial enlargement and
F contribute to a reduced sense of health and vigor. A third is that
oth asymptomatic and symptomatic AF episodes directly affect
he QoL via a reduced cardiac output or exercise intolerance, for
xample, even when the episodes themselves are not perceived.
ur results that showed a correlation between the number of days
f AF and the QoL scores would ﬂatly rule out the ﬁrst hypothesis,
nd make the third hypothesis more likely than the second, since
iseases accompanying AF vary, giving no reason for a linear
elationship between the AF episode frequency and a reduced QoL.
Our data showed that there were no signiﬁcant changes in the
verage scores of the 3 components of the AFQLQ between that atardiology 64 (2014) 64–69
baselineandatoneyear.However, therewerecorrelationsbetween
the asymptomatic episode frequency and AFQLQ2 and AFQLQ3 at
one year which were not observed at baseline. The exact reason
for this ﬁnding is unknown, but we speculate that AF patients
may have some feeling of deterioration of their QoL because of
either symptomatic or asymptomatic AF episodes, as mentioned
above [35]. Symptomatic AF episodes directly reduce theQoL, but if
the symptomatic AF episodes reduced, the asymptomatic episodes
may cause a decrease in the QoL. In other words asymptomatic AF
usually hides behind symptomatic AF, but if the symptomatic AF
decreases, asymptomatic AF may become unveiled and inﬂuence
the AFQLQ2 (the severity of symptoms) and AFQLQ3 (the limita-
tions in the activities and mental anxiety).
Persistent AF
After the initial diagnosis of paroxysmal AF, there is a slow but
steady progression to persistent AF. Our data showed that 13% of
patientsprogressed topersistentAF in1yearbut theydidnot report
a decrease in the QoL as compared to baseline. A previous study
by Peinado et al. [23] compared the QoL in 3 different types of AF
(paroxysmal, persistent, and permanent). They showed, in addition
to no signiﬁcant difference in the QoL among the different types of
AF, that patients with permanent AF were less symptomatic and
had better preserved psychological dimensions than those with
paroxysmal AF, which they attributed to a better adaptation to the
condition. Patients in whom the disease is chronic may have the
perception that the symptoms have become milder or that they
have even disappeared [23].
Study limitations
The present study has several limitations. Our substudy was
based on the J-RHYTHM II study data, in which all patients had
hypertension in addition to paroxysmal AF, and therefore may
not represent AF patients without hypertension. We did not have
control subjects and did not use a generic health-related QoL
questionnaire. The period of follow-up was short at 12 months.
Therefore, we cannot draw conclusions about the QoL for patients
with AF with long-standing disease. We used counts of AF from
TTM of a 30 s duration daily for over a month as a measure of the
AFburden,which obviously underestimated the actual number and
duration of AF episodes. However, asymptomatic episodes of AF
still accounted for 64%of the total AF episodes detected in thisman-
ner, which is not that much smaller than, say, the 88% found in the
CARISMA study that used a cardiac implantable electronic device
to detect asymptomatic AF episodes [18].
Conclusions
In patients with paroxysmal AF, asymptomatic AF episodes
appear to reduce aspects of the QoL associated with mental anx-
iety/limitations in daily activities, and the perception of the AF
symptom severity. Our study suggests that asymptomatic AF also
contributes to a detriment in the QoL, and that elimination of all AF
whether perceived or not, is beneﬁcial not only from a clinical, pro-
gnostic point as is well known, but likely also for the psychological
well-being of the patient.
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